Leuko
Boston, Massachusetts, United States
Leuko is developing the first non-invasive white blood cell device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible - it requires patient travel, blood draws and laboratory infrastructure. Based on MIT research, Leuko is re-imagining the way to perform these tests without extracting blood and in a portable device.
Company Info
- Founded
- 2017
- Website
- leuko.com/
Only accessible to MedStartr community members.
Join nowWhat do you think of Leuko?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.
Comments
Comments from new members are shown once the company's team has approved them. Please follow the community rules.
Sign in to join the conversation.
Sign in to comment